Approximately 17 million people in the United States have type 2 diabetes, and the prevalence continues to rise.1 More than 45% of patients with end-stage renal disease have type 2 diabetes as an etiology, and a patient with type 2 diabetes has the same risk of developing an acute coronary syndrome (unstable angina, myocardial infarction [MI]) over the next 10 years as someone who has had an acute coronary syndrome in the past.2 In addition to these complications, type 2 diabetes also increases the risk of blindness, neuropathy, and amputation.3
Approximately 17 million people in the United States have type 2 diabetes, and the prevalence continues to rise.1 More than 45% of patients with end-stage renal disease have type 2 diabetes as an etiology, and a patient with type 2 diabetes has the same risk of developing an acute coronary syndrome (unstable angina, myocardial infarction [MI]) over the next 10 years as someone who has had an acute coronary syndrome in the past.2 In addition to these complications, type 2 diabetes also increases the risk of blindness, neuropathy, and amputation.3
Studies repeatedly have demonstrated that improved glycemic control benefits patients with diabetes.4,5 In fact, for each percentage point reduction in glycosolated hemoglobin A1c (HbA1c) (eg, from 8.0% to 7.0%), a patient's risk of MI and microvascular complications has been shown to decrease by 16% and 25%, respectively.5
METHODS
Program description. The MAP evaluated in this study has been thoroughly described in a previous publication7 and therefore will be reviewed only briefly here.
The pharmacy-managed MAP was established in cooperation with University of Connecticut's School of Pharmacy in August 2002. Patients are referred to the program through the outpatient social services department, generally after patient applications for state entitlements are denied. On referral, patients are interviewed to obtain demographic, medication, financial, and insurance information and are assisted by program staff in completing and submitting applications to pharmaceutical manufacturers (an average of 4 hours per week is spent on such tasks). Eligibility criteria and enrollment requirements to obtain free medications from manufacturers vary but generally include documentation of limited income, lack of prescription drug coverage, and ineligibility for other forms of both public and private assistance. It is important to note that most medications obtainable through manufacturers' programs are "branded," with access to generic drugs available only through a few programs (ie, Rx Outreach). Only medications for chronic disease states, such as diabetes or hyperlipidemia, are sought. Prescribers are consulted to discuss the patient's current and future drug needs and to complete their sections of applications.
Manufacturer approval of applications and shipping of drugs generally takes 4 to 6 weeks. To address this lag time in receiving pharmaceuticals, those patients thought to be eligible are immediately authorized to receive medication for which they applied, free of charge, from the outpatient pharmacy. Patients typically are approved for 3-month intervals by manufacturer programs.
After initial patient enrollment in the MAP, patients are scheduled to return to the program office on a quarterly basis to be reassessed for eligibility, to identify newly prescribed and eligible medications, and to complete renewal applications and update financial documentation. Patients are contacted via telephone when renewal appointments need to be set or when additional information is required for manufacturer approval.
David Calabrese of OptumRx Talks Top Three Drugs in Pipeline, Industry Trends in Q2
July 1st 2020In this week's episode of Tuning Into The C-Suite podcast, MHE's Briana Contreras chatted with David Calabrese, R.Ph, MHP, who is senior vice president and chief pharmacy officer of pharmacy care services company, OptumRx. David is also a member of Managed Healthcare Executives’ Editorial Advisory Board. During the discussion, he shared the OptumRx Quarter 2 Drug Pipeline Insights Report of 2020. Some of the information shared includes the three notable drugs currently being reviewed or those that have been recently approved by the FDA. Also discussed were any interesting industry trends to watch for.
Listen
FDA Advisory Committee Votes Down Sotagliflozin in Type 1 Diabetes and CKD
November 1st 2024Committee members said there was uncertainty around sotagliflozin in patients with kidney disease. The FDA is currently reviewing the oral therapy as an adjunct to insulin to help control glycemic levels in adults with type 1 diabetes and chronic kidney disease. The agency’s goal date is Dec. 20, 2024.
Read More
Diabetes Management & Telehealth with Leslie Kolb
June 11th 2020Association of Diabetes Care and Education Specialists, chief science and practice officer, Leslie Kolb chats with MHE Associate Editor Briana Contreras in MHE's newest podcast Tuning into the C-Suite about diabetes management and how it's affected by the use of telehealth, especially during the current and trying times of the COVID-19 pandemic.
Listen